| Literature DB >> 28419759 |
Mustafa Fazli1,2, Morten Rybtke2, Elisabeth Steiner3, Elisabeth Weidel4, Jens Berthelsen2, Julie Groizeleau2, Wu Bin5, Boo Zhao Zhi5, Zhang Yaming5, Volkhard Kaever6, Michael Givskov2,7, Rolf W Hartmann4, Leo Eberl3, Tim Tolker-Nielsen2.
Abstract
Knowledge about the molecular mechanisms that are involved in the regulation of biofilm formation is essential for the development of biofilm-control measures. It is well established that the nucleotide second messenger cyclic diguanosine monophosphate (c-di-GMP) is a positive regulator of biofilm formation in many bacteria, but more knowledge about c-di-GMP effectors is needed. We provide evidence that c-di-GMP, the alternative sigma factor RpoN (σ54), and the enhancer-binding protein BerB play a role in biofilm formation of Burkholderia cenocepacia by regulating the production of a biofilm-stabilizing exopolysaccharide. Our findings suggest that BerB binds c-di-GMP, and activates RpoN-dependent transcription of the berA gene coding for a c-di-GMP-responsive transcriptional regulator. An increased level of the BerA protein in turn induces the production of biofilm-stabilizing exopolysaccharide in response to high c-di-GMP levels. Our findings imply that the production of biofilm exopolysaccharide in B. cenocepacia is regulated through a cascade involving two consecutive transcription events that are both activated by c-di-GMP. This type of regulation may allow tight control of the expenditure of cellular resources.Entities:
Keywords: zzm321990Burkholderia cenocepaciazzm321990; zzm321990berBzzm321990; zzm321990rpoNzzm321990; Biofilm; c-di-GMP
Mesh:
Substances:
Year: 2017 PMID: 28419759 PMCID: PMC5552954 DOI: 10.1002/mbo3.480
Source DB: PubMed Journal: Microbiologyopen ISSN: 2045-8827 Impact factor: 3.139
Bacterial strains and plasmids used in the study
| Strain or plasmid | Relevant characteristic(s) | Reference or source |
|---|---|---|
| Strains | ||
|
| Clinical isolate from a cystic fibrosis patient | Carlier et al., |
|
| Used for standard DNA manipulations | Invitrogen |
|
| Used for protein expression and purification | GE Life Sciences |
| Plasmids | ||
| pBBR1MCS5 | Broad‐host‐range cloning vector; Gmr | Kovach et al., |
| pRK404A | Broad‐host‐range cloning vector; Tetr | Ditta et al., |
| pJN105 | Cloning vector; | Newman & Fuqua, |
| pRK600 | Helper plasmid in matings; ori‐ColE1 RK‐mob+ RK2‐tra+; Cmr | Kessler, de Lorenzo, & Timmis, |
| pmini‐Tn7‐kan‐ | Delivery vector for mini‐Tn7‐kan‐ | Norris, Kang, Wilcox, & Hoang, |
| pUX‐BF13 | Mob+ ori‐R6K; helper plasmid providing theTn7 transposition functions in trans; Ampr | Bao, Lies, Fu, & Roberts, |
| pDAI‐SceI‐ | Cloning vector containing the I‐SceI endonuclease; Tetr | Fazli et al., |
| pGEX‐6P‐2 | Glutathione | GE Life Sciences |
| pDONRPEX18Tp‐SceI‐ | Gateway compatible gene replacement vector based on SceI and pheS; Tpr | Fazli et al., |
| pDONRPEX18Gm‐SceI‐ | Gateway compatible gene replacement vector based on SceI and pheS; Gmr | Fazli et al., |
| pYedQ |
| Ausmees et al., |
| pYedQ2 |
| Fazli et al., |
| pBerA |
| This study |
| pBerB |
| This study |
| pRpoN |
| This study |
| pENTRPEX18Tp‐SceI‐pheS‐ | Gene replacement vector for | This study |
| pENTRPEX18Gm‐SceI‐pheS‐ | Gene replacement vector for | This study |
| pBepB:: | Gene replacement vector used to create | This study |
| pGEX‐6P‐2:: |
| This study |
| pGEX‐6P‐2:: |
| This study |
| pGEX‐6P‐2:: |
| This study |
| pBK‐miniTn7‐KmΩSm1 | miniTn7 delivery vector, Kanr | Koch, Jensen, & Nybroe, |
| pTn7‐berA‐lacZ | Tn7‐based berA‐lacZ promoter fusion. Native rpoN‐binding site. Kanr | This study |
| pTn7‐berA‐lacZ‐rpoNdel | Tn7‐based berA‐lacZ promoter fusion. Deleted RpoN‐binding site. Kanr | This study |
| pTn7‐berA‐lacZ‐rpoNmut | Tn7‐based berA‐lacZ promoter fusion. Mutated RpoN‐binding site. Kanr | This study |
Figure 1Colony morphology on AB agar medium of the wild‐type (WT) strain, the WT strain carrying pYedQ (WT/pYedQ), the representative rpoN transposon‐mutant strain carrying pYedQ (rpoN TnM/pYedQ), and the ΔrpoN and ΔberB strains carrying pYedQ (ΔrpoN/pYedQ and ΔberB/pYedQ)
Figure 2Confocal laser scanning microscope images (CLSM) of SYTO9‐stained, 2‐day‐old flow‐cell biofilms formed by the wild‐type strain, the representative rpoN transposon‐ mutant strain (rpoN TnM) and the complemented rpoN TnM (rpoN TnM/pRpoN) strain. The central images show top‐down shadow projection views, whereas the flanking images show vertical sections through the biofilms. The scale bars correspond to 50 μm
Figure 3Colony morphology on AB agar medium of the wild‐type, ΔrpoN and ΔberA strains harboring pBerB
Figure 4CLSM images of 2‐day‐old flow‐cell biofilms formed by the wild‐type strain, and the ΔberB and the complemented ΔberB (ΔberB/pBerB) strains before and after sodium dodecyl sulfate treatment
Figure 5Colony morphology on AB agar medium of the wild‐type, ΔrpoN, and ΔberB strains harboring pBerA
Figure 6(a) QRT‐PCR analysis of transcript levels of berA (black columns) and bepB (gray columns) genes in c‐di‐GMP‐overproducing strains of the wild‐type (WT/pYedQ), ΔrpoN (ΔrpoN/pYedQ), and ΔberB (ΔberB/pYedQ). Data are normalized to gyrB transcript levels and presented as the fold change with respect to the wild‐type vector control strain for each gene. (b) Determination of berA expression by measuring the β‐galactosidase activity in c‐di‐GMP‐overproducing (pYedQ2‐containing) wild‐type bacteria harboring miniTn7‐inserted berA::lacZ promoter fusions with a native, deleted or mutated RpoN‐binding site. The schematics display the native, deleted and mutated RpoN‐binding site. (c) Determination of bepB expression by measuring the β‐galactosidase activity in c‐di‐GMP‐overproducing bepB::lacZ reporter strains of the wild‐type (WT/pYedQ), ΔrpoN (ΔrpoN/pYedQ), and ΔberB (ΔberB/pYedQ). In all cases (a, b, and c), data are representative of three independent biological experiments, and bars indicate standard deviations
Figure 7Binding of BerB and RpoN to the promoter region of the berA gene assessed by the use of EMSA. The RpoN and BerB proteins, and c‐di‐GMP were added into the EMSA reaction mixtures as indicated. EMSA, electrophoretic mobility shift assay
Figure 8Mapping of BerB binding sites at the berA promoter region using exonuclease III footprinting. Protection of distinct DNA sequences by BerB, but not by BSA, was visualized by native gradient TBE gel electrophoresis (a). The size of the protected DNA fragments was estimated by denaturing Urea‐TBE electrophoresis with synthesized ssDNA ladders (b). Thereby putative BerB binding sites at the berA promoter region could be mapped as shown (c)
Figure 9SPR sensorgrams indicating the binding of BerA (a) and BerB (b) to biotinylated c‐di‐GMP are depicted in the upper part of the figure. A range of concentrations was used for each protein. The signal heights in the steady state were taken to approximate the values for each protein by scrubber software. The affinity fits for BerA (c) and BerB (d) are shown in the lower part of the figure. SPR, surface plasmon resonance
Figure 10Model for the regulation of biofilm formation by c‐di‐GMP, BerB, and RpoN. BerB binds c‐di‐GMP and activates RpoN‐dependent transcription of the berA gene coding for the c‐di‐GMP‐binding transcriptional regulator BerA. An increased level of the BerA protein in turn induces the production of biofilm‐stabilizing Bep exopolysaccharide in response to high c‐di‐GMP levels